Spontaneous orofacial dyskinesias in a captive cynomolgus monkey: implications for tardive dyskinesia.
We describe a syndrome of spontaneous orofacial dyskinesias and cage stereotypies in a singly housed adult cynomolgus monkey never previously exposed to neuroleptic drugs. Abnormal movements were readily suppressed by acute treatment with haloperidol (0.03-0.24 mg/kg i.m.) or SCH23390 (0.05-0.2 mg/kg i.m.) but not by physostigmine (0.005-0.04 mg/kg i.m.) or scopolamine (0.0025-0.04 mg/kg i.m.). The symptomatology and response to pharmacological manipulations was indistinguishable from that previously attributed to chronic neuroleptic treatment in primates. Our findings indicate that neuroleptic-induced tardive dyskinesias in most primate studies have not been clearly demonstrated.
Rupniak
N M
NM
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, England.
Tye
S J
SJ
Steventon
M J
MJ
Boyce
S
S
Iversen
S D
SD
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology*; D005149:Facial Expression; D005152:Facial Muscles / Q000503:physiopathology*; D006220:Haloperidol / Q000494:pharmacology; D008252:Macaca fascicularis / Q000502:physiology*; D008409:Mastication / Q000502:physiology; D009069:Movement Disorders / Q000503:physiopathology*; D010830:Physostigmine / Q000494:pharmacology; D012601:Scopolamine / Q000494:pharmacology; D013239:Stereotyped Behavior / Q000502:physiology*
D001552:Benzazepines; D010830:Physostigmine; D012601:Scopolamine; D006220:Haloperidol